follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Eisai gets $65M for U.S. rights to Targretin

By Joe Arney
February 21. 2013 8:38AM

Back to TopCommentsPrint
Eisai Inc.’s U.S. operations announced today that it sold the U.S. rights to its Targretin capsules and gel to Montreal-based Valeant Pharmaceuticals International Inc.


Eisai, in Woodcliff Lake, received $65 million up front, plus potential future payments based on certain milestones. Valeant assumes responsibilities for all regulatory obligations associated with the product in the United States.

 
advertisement

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top